Long-term efficacy of platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention

JAMA

Volumn 287, Issue 5, 2002, Pages 618-621

  Conor O'Shea, J ^a   Buller, Christopher E ^b   Cantor, Warren J ^c   Bleakley Chandler, A ^d   Cohen, Eric A ^e   Cohen, David J ^f   Gilchrist, Ian C ^g   Kleiman, Neal S ^h   Labinaz, Marino ⁱ   Madan, Mina ^e   Hafley, Gail E ^a   Califf, Robert M ^a   Kitt, Michael M ^j   Strony, John ^k   Tcheng, James E ^a  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^b VANCOUVER GENERAL HOSPITAL   (Canada)

^c ST MICHAEL'S HOSPITAL   (Canada)

^d University Hospital Augusta   (United States)

^e SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^f BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^g PENN STATE COLLEGE OF MEDICINE   (United States)

^h BAYLOR COLLEGE OF MEDICINE   (United States)

ⁱ UNIVERSITY OF OTTAWA HEART INSTITUTE   (Canada)

^j MILLENNIUM PHARMACEUTICALS INC   (United States)

^k MERCK RESEARCH LABORATORIES   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; CLOPIDOGREL; EPTIFIBATIDE; FIBRINOGEN RECEPTOR; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; PLACEBO; PYRIDINE DERIVATIVE; TICLOPIDINE; TIROFIBAN;

ADULT; AGED; ARTICLE; BOLUS INJECTION; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY STENT; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; FOLLOW UP; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART MUSCLE REVASCULARIZATION; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOMES RESEARCH; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME;

EID: 0037028774     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.287.5.618     Document Type: Article

References (16)

1. Glycoprotein IIb/IIIa integrin blockade
2. Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ischemic heart disease
3. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/ IIIa receptor in high-risk coronary angioplasty
4. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization
5. Randomised placebo-controlled and balloon angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade
6. Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention, IMPACT-II
7. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: The CAPTURE study
8. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty
9. Design and methodology of the ESPRIT trial: Evaluating a novel dosing regimen of eptifibatide in percutaneous coronary intervention
10. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): A randomised, placebo-controlled trial
11. Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: Results from a multicentre randomised trial
12. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization
13. GP IIb-IIIa antagonists demonstrate a dose-dependent inhibition and potentiation of soluble CD40L (CD154) release during platelet stimulation
14. Influence of diabetes mellitus on early and late outcome after percutaneous transluminal coronary angioplasty
15. Diabetes mellitus, glycoprotein IIb/IIIa blockade, and heparin: Evidence for a complex interaction in a multicenter trial